The JAK2V617F Mutation Seen in Myeloproliferative Neoplasms (MPNs) Occurs
in Patients with Inflammatory Bowel Disease: Implications of a Pilot Study
14
resent the clinical manifestation of a shared genetic pre-
disposition for IBD and MPN in the form of the 46/1
haplotype, and therefore, warrant not only large scale
testing for MPNs in patients with IBD, but therapeutic
trials of drugs with potential to simultaneously improve
outcomes for both diseases.
5. Acknowledgements
1) E. T. K. was supported by the Johns Family Fel-
lowship in Myeloproliferative Neoplasms, The Cancer
Research and Treatment Fun d, I nc., Ne w Y or k, NY.
2) We are grateful to Jacob Weiser for conducting the
EMR screen to identify the patients for this study.
3) This work was supported in p art by th e William and
Judy Higgins Trust of the Cancer Research and Treat-
ment Fund, I n c., New York, NY.
REFERENCES
[1] P. M. Irving, K. J. Pasi a nd D. S. Rampton, “Thrombosis
and Inflammatory Bowel Disease,” Clinical Gastroen-
terology and Hepatology, Vol. 3, No. 7, 2005, pp. 617-
628. http://dx.doi.org/10.1016/S1542-3565(05)00154-0
[2] D. Silvio, C. de la Motte and C. Fiocchi, “Platelets in
Inflammatory Bowel Disease: Clinical, Pathogenic, and
Therapeutic Implications,” American Journal of Gastro-
enterology, Vol. 99, No. 5, 2004, pp. 938-945.
http://dx.doi.org/10.1111/j.1572-0241.2004.04129.x
[3] M. Griesshammer, M. Bangerte r, T. Sauer, R. Wennauer,
L. Bergmann and H. Heimpel, “Aetiology and Clinical
Significance of Thrombocytosis: Analysis of 732 Patients
with an Elevated Platelet Count,” Journal of Internal
Medicine, Vol. 245, No. 3, 1999, pp. 295-300.
http://dx.doi.org/10.1046/j.1365-2796.1999.00452.x
[4] A. I. Schafer, “Thrombocytosis,” New England Journal of
Medicine, Vol. 350, No. 12, 2004, pp. 1211-1219.
http://dx.doi.org/10.1056/NEJMra035363
[5] A. M. Vanucchi and T. Barbui, “Thrombocytosis and
Thrombosis. Hematology, Vol. 2007, No. 1, 2007, pp.
363-370.
http://dx.doi.org/10.1182/asheducation-2007.1.363
[6] B. Anger, J. W. Janssen, H. Schrezenmeier, R. Hehlmann,
H. Heimpel and C. R. Bartram, “Clonal Analysis of Chro-
nic Myeloproliferative Disorders Using X-Linked DNA
Polymorphisms,” Le ukemia, Vol. 4, No. 4, 1990, pp. 258-
261.
[7] Y. L. Wang, K. Vandris, A. V. Jones, N. C. Cross, P.
Christos, F. Adriano and R. T. Silver, “JAK2 Mutations
Are Present in All Cases of Polycythemia Vera,” Leuke-
mia, Vol. 22, No. 6, 2008, p. 1289.
http://dx.doi.org/10.1038/sj.leu.2405047
[8] J. J. Kiladjian, “The Spectrum of JAK2-Positive Mye-
loproliferative Neoplasms,” HEMATOLOGY American
Society of Hematology Education Program, Vol. 2012,
No. 1, 2012, pp. 561-566.
[9] S. Y. Kristinsson, O. Landgren, J. Samuelsson, M. Bjor-
kolm and L. R. Goldin, “Autoimmunity and the Risk of
Myeloproliferative Neoplasms,” Haematologica, Vol. 95,
No. 7, 2010, pp. 1216-1220.
http://dx.doi.org/10.3324/haematol.2009.020412
[10] A. V. Jones and N. C. P. Cross, “No Association between
Myeloproliferative Neoplasms and the Crohn’s Dis-
ease-Associated STAT3 Predisposition SNP rs744166,”
Haematologica, Vol. 95, No. 7, 2010, pp. 1226-1227.
[11] J. C. Barrett, S. Hansoul, D. L. Nicolae, J. H. Cho, R. H.
Duerr, J. D. Rioux, et al., “Genomewide Association De-
fines More Than 30 Distinct Susceptibility Loci for
Crohn’s Disease,” Nature Genetics, Vol. 40, No. 8, 2008,
pp. 955-962. http://dx.doi.org/10.1038/ng.175
[12] K. Wang, H. Zhang, S. Kugathasan, V. Annese, J. P.
Bradfield, R. K. Russell, et al., “Diverse Genome-Wide
Association Studies Associate the IL12/IL23 Pathway
with Crohn Disease,” The American Journal of Human
Genetics, Vol. 84, No. 3, 2009, pp. 399-405.
http://dx.doi.org/10.1016/j.ajhg.2009.01.026
[13] A. V. Jones, A. Chase, R. T. Silver, D. Oscier, K. Zoi, Y.
L. Wang, et al., “JAK2 Haplotype Is a Major Risk Factor
for the Development of Myeloproliferative Neoplasms,”
Nature Genetics, Vol. 41, No. 4, 2009, pp. 446-449.
http://dx.doi.org/10.1038/ng.334
[14] D. Olcaydu, A. Harutyunyan, R. Jager, T. Berg, B. Gis-
slinger, I. Pabinger, et al., “A Common JAK2 Haplo-
type Confers Susceptibility to Myeloproliferative Neo-
plasms,” Nature Genetics, Vol. 41, No. 4, 2009, pp. 450-
454. http://dx.doi.org/10.1038/ng.341
[15] O. Kilpivaara, S. Mukherjee, A. M. Schram, M. Wadleigh,
A. Mullally, B. L. Ebert, et al., “A Germline JAK2 SNP
Is Associated with Predisposition to the Development of
JAK2(V617F)-Positive Myeloproliferative Neoplasms,”
Nature Genetics, Vol. 41, No. 4, 2009, pp. 455-459.
http://dx.doi.org/10.1038/ng.342
[16] S. Brand, “Crohn’s Disease: Th1, Th17 or Both? The
Change of a Paradigm: New Immunological and Genetic
Insights Implicate Th17 Cells in the Pathogenesis of
Crohn’s Disease,” Gut, Vol. 58, No. 8, 2009, pp. 1152-
1167. http://dx.doi.org/10.1136/gut.2008.163667
[17] G. Finazzi, X. T. Gregg, T. Barbui and J. T. Prchal, “Idio-
pathic Erythrocytosis and Other Non-Clonal Polycythe-
mias,” Best Practice & Research: Clinical Haematology,
Vol. 19, No. 3, 2006, pp. 471-482.
http://dx.doi.org/10.1016/j.beha.2005.07.006
[18] J. L. Spiva k and R. T. Sil ver, “The Re vised Worl d Health
Organization Diagnostic Criteria for Polycythemia Vera,
Essential Thrombocytosis, and Primary Myelofibrosis:
An Alternative Proposal,” Blood, Vol. 112, No. 2, 2008,
pp. 231-239.
http://dx.doi.org/10.1182/blood-2007-12-128454
[19] R. T. Silver, W. Chow, A. Orazi, S. P. Arles and S. J.
Goldsmith, “Evaluation of WHO Criteria for Diagnosis of
Polycythemia Vera: A Prospective Analysis,” Blood, Vol.
122, No. 11, 2013, pp. 1881-1886.
http://dx.doi.org/10.1182/blood-2013-06-508416
[20] G. Bergamaschi, A. Di Sabatino, R. Albertini, S. Ardiz-
zone, P. Biancheri, E. Bonetti, et al., “Prevalence and Pa-
Open Access IJCM